Update Review about Metabolic Myopathies
Open accessThe DOI matches its Crossref record; 93 of the 98 references it cites were found in a registry or an index.
Abstract
The aim of this review is to summarize and discuss recent findings and new insights in the etiology and phenotype of metabolic myopathies. The review relies on a systematic literature review of recent publications. Metabolic myopathies are a heterogeneous group of disorders characterized by mostly inherited defects of enzymatic pathways involved in muscle cell metabolism. Metabolic myopathies present with either permanent (fixed) or episodic abnormalities, such as weakness, wasting, exercise-intolerance, myalgia, or an increase of muscle breakdown products (creatine-kinase, myoglobin) during exercise. Though limb and respiratory muscles are most frequently affected, facial, extra-ocular, and axial muscles may be occasionally also involved. Age at onset and prognosis vary considerably. There are multiple disease mechanisms and the pathophysiology is complex. Genes most recently related to metabolic myopathy include PGM1, GYG1, RBCK1, VMA21, MTO1, KARS, and ISCA2. The number of metabolic myopathies is steadily increasing. There is limited evidence from the literature that could guide diagnosis and treatment of metabolic myopathies. Treatment is limited to mainly non-invasive or invasive symptomatic measures. In conclusion, the field of metabolic myopathies is evolving with the more widespread availability and application of next generation sequencing technologies worldwide. This will broaden the knowledge about pathophysiology and putative therapeutic strategies for this group of neuromuscular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, premature fatigue (i.e. a faster drop in force) related to decreased mitochondrial oxidative capacity has been shown to precede overt muscle weakness in mouse models with mitochondrial dysfunction, as well as in patients with mitochondrial myopathies (Finsterer, 2020; Tarnopolsky, 2016; Yamada et al., 2012).”
From Impaired aerobic capacity and premature fatigue preceding muscle weakness in the skeletal muscle Tfam-knockout mouse model (2021) · cites this paper as Finsterer, 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results extend those from previous studies showing severe muscle weakness in more advanced stages of the disease (Gineste et al., 2015; Wredenberg et al., 2002), and support those reported in patients related to a progression from early premature fatigue to disabling muscle weakness at rest (Finsterer, 2020; Tarnopolsky, 2016).”
From Impaired aerobic capacity and premature fatigue preceding muscle weakness in the skeletal muscle Tfam-knockout mouse model (2021) · cites this paper as Finsterer, 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boisson, B., Laplantine, E., Prando, C., Giliani, S., Israelsson, E., Xu, Z., Abhyankar, A., Israël, L., Trevejo-Nunez, G., Bogunovic, D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2457 · Cited by 474 · cited 1×
“Mutations in RBCK1 were first described in three children with failure to thrive, chronic auto-inflammation and recurrent episodes of sepsis [33].”
BackgroundTreatment recommendations in long‐chain fatty acid oxidation defects: consensus from a workshop
Spiekerkoetter, U., Lindner, M., Santer, R., Grotzke, M., Baumgartner, M. R., Boehles, H., Das, A., Haase, C., Hennermann, J. B., Karall, D., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1126-8 · Cited by 220 · cited 2×
“Bezafibrate has not been shown to be effective in vivo [92].”
BackgroundThe emerging phenotype of late-onset Pompe disease: A systematic literature review
Chan, J., Desai, A. K., Kazi, Z. B., Corey, K., Austin, S., Hobson-Webb, L. D., Case, L. E., Jones, H. N., & Kishnani, P. S. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.12.004 · Cited by 188 · cited 2×
“To assess the risk of relatives of an index patient, enzymology (GAA activity assay) is recommended as the initial screening test before targeted mutation analysis is carried out [73,74].”
BackgroundGlycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome
Sentner, C. P., Hoogeveen, I. J., Weinstein, D. A., Santer, R., Murphy, E., McKiernan, P. J., Steuerwald, U., Beauchamp, N. J., Taybert, J., Laforêt, P., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9932-2 · Cited by 178 · cited 2×
“Chronic complications included liver cirrhosis, liver adenoma, or hepatocellular carcinoma in 11%, cardiomyopathy in 15%, heart failure in 58%, myalgia in 34%, and diabetes in 9% of patients [23].”
BackgroundDanon disease: a phenotypic expression of LAMP-2 deficiency
Endo, Y., Furuta, A., & Nishino, I. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1385-4 · Cited by 176 · cited 2×
“There are three isoforms, LAMP2A, LAMP2B, and LAMP2C, of which LAMP2B is the major isoform expressed in muscle tissue [77].”
BackgroundPolyglucosan body myopathy caused by defective ubiquitin ligase RBCK1
Nilsson, J., Schoser, B., Laforet, P., Kalev, O., Lindberg, C., Romero, N. B., Dávila López, M., Akman, H. O., Wahbi, K., Iglseder, S., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23963 · Cited by 146 · cited 2×
“Extensive deposition of polyglucosan was found in myocytes and cardiomyocytes, hence the term PGBM-1 was adopted [34].”
BackgroundArnold, G. L., Hove, J. V., Freedenberg, D. L., Strauss, A. W., Longo, N., Burton, B. K., Garganta, C. L., Ficicioglu, C. H., Cederbaum, S. D., Harding, C. O., et al. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.09.008 · Cited by 146 · cited 1×
“Fat metabolism disorders should be generally treated with a carbohydrate-rich diet to avoid a catabolic state [92,93].”
Backgroundβ‐enolase deficiency, a new metabolic myopathy of distal glycolysis
Comi, G. P., Fortunato, F., Lucchiari, S., Bordoni, A., Prelle, A., Jann, S., Keller, A., Ciscato, P., Galbiati, S., Chiveri, L., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1095 · Cited by 131
GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
Reuser, A. J. J., van der Ploeg, A. T., Chien, Y., Llerena, J. C., Abbott, M., Clemens, P. R., Kimonis, V. E., Leslie, N., Maruti, S. S., Sanson, B., et al. (2019) · Human Mutation · doi:10.1002/humu.23878 · Cited by 112
Sharpe, A. J., & McKenzie, M. (2018) · Cells · doi:10.3390/cells7060046 · Cited by 108
ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder
Al-Hassnan, Z. N., Al-Dosary, M., Alfadhel, M., Faqeih, E. A., Alsagob, M., Kenana, R., Almass, R., Al-Harazi, O. S., Al-Hindi, H., Malibari, O. I., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102592 · Cited by 102 · cited 1×
“Muscle biopsy may show increased fiber size variability, increased fiber atrophy and reduced respiratory chain activity in some of these patients [61].”
BackgroundHepatic glycogen storage disorders: what have we learned in recent years?
Burda, P., & Hochuli, M. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000181 · Cited by 97 · cited 1×
“For GSD III, a high protein diet has been reported to improve cardiomyopathy [90].”
BackgroundDanon disease – dysregulation of autophagy in a multisystem disorder with cardiomyopathy
Rowland, T. J., Sweet, M. E., Mestroni, L., & Taylor, M. R. G. (2016) · Journal of Cell Science · doi:10.1242/jcs.184770 · Cited by 97 · cited 1×
“Thus, LAMP2 deficiency leads to failure and disturbance of macroautophagy [78].”
BackgroundThe role of αB-crystallin in skeletal and cardiac muscle tissues
Dimauro, I., Antonioni, A., Mercatelli, N., & Caporossi, D. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0866-x · Cited by 93 · cited 1×
“HSPB8 nDNA autophagy No Yes (neuropathy) [59]”
Polyglucosan storage myopathies
Hedberg‐Oldfors, C., & Oldfors, A. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.08.006 · Cited by 90 · cited 5×
“Polyglucosan has a typical fibrillar appearance on electron microscopy and can aggregate into dense inclusions (polyglucosan bodies) [32].”
BackgroundInfluentialCarnitine palmitoyltransferase II deficiency
Wieser, T., Deschauer, M., Olek, K., Hermann, T. M., & Zierz, S. (2003) · Neurology · doi:10.1212/01.wnl.0000055901.58642.48 · Cited by 90 · cited 2×
“CPT2 encodes carnitine palmitoyl-transferase-II, a key enzyme involved in LCFA oxidation [46].”
BackgroundLuna‐Sánchez, M., Hidalgo‐Gutiérrez, A., Hildebrandt, T. M., Chaves‐Serrano, J., Barriocanal‐Casado, E., Santos‐Fandila, Á., Romero, M., Sayed, R. K., Duarte, J., Prokisch, H., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606345 · Cited by 81 · cited 3×
“Coenzyme-Q not only functions as an electron donor and acceptor within the respiratory chain, but also performs several other functions in cellular metabolism [65].”
BackgroundInfluentialPrimary Carnitine Deficiency and Newborn Screening for Disorders of the Carnitine Cycle
Longo, N. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000448321 · Cited by 75 · cited 1×
“SLC22A5 PCD FA import Yes Yes (cardiomyopathy) [38]”
BackgroundDefective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome
Garone, C., D’Souza, A. R., Dallabona, C., Lodi, T., Rebelo‐Guiomar, P., Rorbach, J., Donati, M. A., Procopio, E., Montomoli, M., Guerrini, R., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx314 · Cited by 75 · cited 1×
“MRM2 nDNA mt rRNA No Yes (MELAS-like) [60]”
BackgroundECHS1 Mutations Cause Combined Respiratory Chain Deficiency Resulting in Leigh Syndrome
Sakai, C., Yamaguchi, S., Sasaki, M., Miyamoto, Y., Matsushima, Y., & Goto, Y.-I. (2014) · Human Mutation · doi:10.1002/humu.22730 · Cited by 69 · cited 3×
“In a boy with ECHS1 deficiency, ECHS1 protein expression was severely depleted in the patient’s skeletal muscle and patient-derived myoblasts [45].”
BackgroundMethodInfluentialPiekutowska‐Abramczuk, D., Assouline, Z., Mataković, L., Feichtinger, R. G., Koňaříková, E., Jurkiewicz, E., Stawiński, P., Gušić, M., Koller, A., Pollak, A., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.01.008 · Cited by 69 · cited 1×
“NDUFB8 nDNA complex-I ↓ No Yes (parkinsonism) [57]”
Tarnopolsky, M. A. (2016) · Continuum · doi:10.1212/con.0000000000000403 · Cited by 61
First-line genomic diagnosis of mitochondrial disorders
Raymond, F. L., Horváth, R., & Chinnery, P. F. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0022-1 · Cited by 59 · cited 1×
“There is increasing evidence that whole exome sequencing (WES) is the method of choice for diagnosing conditions such as CoQ-deficiency [87] or MIDs in general [88].”
BackgroundKrenn, M., Salzer, E., Simonitsch-Klupp, I., Rath, J., Wagner, M., Haack, T. B., Strom, T. M., Schänzer, A., Kilimann, M. W., Schmidt, R. L. J., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-017-8710-x · Cited by 58 · cited 1×
“RBCK1 PGBM-1 Yes Yes (cardiomyopathy, infections) [21]”
Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII)
Musumeci, O., Bruno, C., Mongini, T., Rodolico, C., Aguennouz, M., Barca, E., Amati, A., Cassandrini, D., Serlenga, L., Vita, G., et al. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.10.022 · Cited by 57
Béhin, A., Acquaviva, C., Souvannanorath, S., Streichenberger, N., Attarian, S., Bassez, G., Brivet, M., Fouilhoux, A. C., Labarre-Villa, A., Laquerrière, A., et al. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.11.008 · Cited by 56 · cited 1×
“ETFDH MADD FAOD Yes Yes (skin disease, hepatopathy, hypoglycemia) [39]”
BackgroundDefining the Phenotype and Assessing Severity in Phosphoglucomutase-1 Deficiency
Wong, S., Beamer, L. J., Gadomski, T., Honzík, T., Mohamed, M., Wortmann, S. B., Holmefjord, K. S. B., Mork, M., Bowling, F. G., Sykut‐Cegielska, J., et al. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.04.021 · Cited by 54
Clinical and molecular spectrum of thymidine kinase 2-related mtDNA maintenance defect
Wang, J., Kim, E., Dai, H., Stefans, V., Vogel, H. S., Jasmi, F. A., Vergano, S. A. S., Castro, D., Bernes, S. M., Bhambhani, V., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.04.012 · Cited by 51
Bottillo, I., Giordano, C., Cerbelli, B., D’Angelantonio, D., Lipari, M., Polidori, T., Majore, S., Bertini, E., D’Amico, A., Giannarelli, D., et al. (2016) · Cardiovascular Pathology · doi:10.1016/j.carpath.2016.07.005 · Cited by 48 · cited 1×
“Though Danon disease is an X-linked disorder, female carriers of the disease may be also affected, particularly in the heart [84].”
BackgroundExercise in muscle glycogen storage diseases
Preisler, N. R., Haller, R. G., & Vissing, J. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9771-y · Cited by 43 · cited 2×
“Ample evidence has been collected during recent years that exercise training in the various types of GSD can be beneficial regarding exercise tolerance and increasing fatty acid oxidation [7].”
BackgroundPGM1 deficiency: Substrate use during exercise and effect of treatment with galactose
Voermans, N. C., Preisler, N. R., Madsen, K. L., Janssen, M. C. H., Küsters, B., Bakar, N. A., Conte, F., Lamberti, V. M. L., Nusman, F., van Engelen, B. G. M., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.01.014 · Cited by 42 · cited 1×
“PGM1 GSD XIV No Yes (hypoglycaemia, hepatopathy) [18,19]”
BackgroundThe genotypic and phenotypic spectrum of MTO1 deficiency
O’Byrne, J. J., Tarailo‐Graovac, M., Ghani, A., Champion, M., Deshpande, C., Dursun, A., Özgül, R. K., Freisinger, P., Garber, I., Haack, T. B., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.11.003 · Cited by 39 · cited 4×
“Patients with complete loss of MTO1 are not viable [64].”
BackgroundInfluentialOndrušková, N., Honzík, T., Vondráčková, A., Tesařová, M., Zeman, J., & Hansíková, H. (2014) · PubMed · Cited by 38
The investigation and management of metabolic myopathies
Olpin, S. E., Murphy, E., Kirk, R., Taylor, R. W., & Quinlivan, R. C. M. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202808 · Cited by 37 · cited 1×
“The myopathic form typically presents with exercise intolerance and recurrent attacks of muscle weakness, muscle cramps, and myoglobinuria precipitated by certain drugs (non-steroidal anti-inflammatory drugs (NSAIDs)), prolonged exercise, episodes of fasting, or stress [47].”
BackgroundLipolysis and lipophagy in lipid storage myopathies
Angelini, C. I., Nascimbeni, A. C., Cenacchi, G., & Tasca, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.04.008 · Cited by 37 · cited 1×
“Typically, triglyceride droplets are excessively stored in muscle tissue in lipid storage diseases [37].”
BackgroundVerrigni, D., Diodato, D., Nottia, M. D., Torraco, A., Bellacchio, E., Rizza, T., Tozzi, G., Verardo, M., Piemonte, F., Tasca, G. A., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12931 · Cited by 37 · cited 3×
“Complex-I activity was reduced by 45% and complex-IV activity was reduced by 72% [62].”
BackgroundInfluentialTherapeutic Strategies for Mitochondrial Disorders
Finsterer, J., & Bindu, P. S. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.06.023 · Cited by 36 · cited 1×
“In case respiratory muscles are involved, invasive or non-invasive artificial ventilation is indicated [94].”
BackgroundSelf-citationPsychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation)
Yardeni, M., Weisman, O., Mandel, H., Weinberger, R., Quarta, G., Salazar‐Mendiguchía, J., García‐Pavía, P., Lobato‐Rodríguez, M. J., Simon, L. F., Dov, F., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38320 · Cited by 36 · cited 1×
“According to a recent study, mental retardation is a core constituent of Danon disease, which is why these patients need to be referred to a neuropsychologist or psychiatrist [81].”
BackgroundLimitations of galactose therapy in phosphoglucomutase 1 deficiency
Nolting, K., Park, J. H., Tegtmeyer, L. C., Zühlsdorf, A., Grüneberg, M., Rust, S., Reunert, J., Chesne, I. D., Debus, V., Schulze‐Bahr, E., et al. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.07.010 · Cited by 36 · cited 1×
“5 g/kg body weight (BW) are not sufficient to restore impaired glycosylation in all patients [89].”
BackgroundMalignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy)
Samad, F., Jain, R., Jan, M. F., Sulemanjee, N., Menaria, P., Kalvin, L., Bush, M. L., Jahangir, A., Khandheria, B. K., & Tajik, A. J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.031 · Cited by 34 · cited 3×
“LAMP2 Lysosome No Yes (cardiomyopathy) [67]”
BackgroundInfluentialDiagnostic pitfall in antenatal manifestations of CPT II deficiency
Boemer, F., Deberg, M. A., Schoos, R., Caberg, J., Gaillez, S., Dugauquier, C., Delbecque, K., François, A., Maton, P., Demonceau, N., et al. (2015) · Clinical Genetics · doi:10.1111/cge.12593 · Cited by 33 · cited 12×
“Nomenclature List of Abbreviations AD Autosomal dominant AR Autosomal recessive CPT-II Carnitine-palmitoyl-transferase deficiency DBS Dried blood spot test EALS Endosomal autophagic lysosomal system EOPD Early onset Pompe disease ERT Enzyme replacement therapy FAOD Fatty acid oxidation disorder FAUD Fatty acid uptake…”
BackgroundInfluentialMolecular diagnosis of coenzyme Q10 deficiency: an update
Yubero, D., Montero, R., Santos‐Ocaña, C., Salviati, L., Navas, P., & Artuch, R. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1478290 · Cited by 33 · cited 1×
“There is increasing evidence that whole exome sequencing (WES) is the method of choice for diagnosing conditions such as CoQ-deficiency [87] or MIDs in general [88].”
BackgroundDodge, J. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00356 · Cited by 32 · cited 3×
“, lysosomal cacostasis) contributes to common neurodegenerative disorders such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), CMT, hereditary spastic paraplegias (HSPs), or multiple systemic atrophy (MSA) (Table 4) [66].”
BackgroundFurther delineation of the phenotypic spectrum of ISCA2 defect: A report of ten new cases
Alfadhel, M., Nashabat, M., Alrifai, M. T., Alshaalan, H., Mutairi, F. A., Alshahrani, S., Plecko, B., Almass, R., Alsagob, M., Almutairi, F. B., et al. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.10.003 · Cited by 31 · cited 3×
“The assembly of ISCs is a vital cellular process for the generation of ISC-containing proteins, which are involved in the regulation of gene expression, respiration, energy production by means of the respiratory chain, sensing of oxygen, and cellular iron concentration [52].”
BackgroundInfluentialThe variable clinical phenotype of three patients with hepatic glycogen synthase deficiency
Kasapkara, Ç. S., Aycan, Z., Açoğlu, E. A., Şenel, S., Oğuz, M. M., & Ceylaner, S. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0317 · Cited by 30 · cited 1×
“GYS2 GSD 0 Yes Yes (cardiomyopathy) [8]”
Update on new muscle glycogenosis
Laforêt, P., Malfatti, E., & Vissing, J. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000484 · Cited by 30 · cited 1×
“The field of muscle glycogenoses has progressed in recent years by the detection of new subtypes and by achieving a better understanding of the pathophysiology of glycogenoses and the physiology of glycogen metabolism [5].”
BackgroundVisuttijai, K., Hedberg‐Oldfors, C., Thomsen, C., Glamuzina, E. E., Kornblum, C., Tasca, G. A., Hernández‐Laín, A., Sandstedt, J., Dellgren, G., Roach, P. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz075 · Cited by 30 · cited 1×
“This indicates that GYG1 is largely disposable for building normal muscle glycogen even without a compensation by GYG2 [31].”
BackgroundMamoune, A., Bahuau, M., Hamel, Y., Serre, V., Pelosi, M., Habarou, F., Nguyen-Morel, M.-A., Boisson, B., Vergnaud, S., Bui, M. T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004711 · Cited by 27 · cited 1×
“ALDOA GSD XII No Yes (anemia, hyperkalemia) [16]”
BackgroundCongenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy
Munteanu, I., Ramachandran, N., Ruggieri, A., Awaya, T., Nishino, I., & Minassian, B. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001499 · Cited by 27 · cited 5×
“XMEA usually progresses to the respiratory muscles, which is why patients become ventilator dependent over time [68].”
BackgroundInfluentialImpaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency
Preisler, N. R., Cohen, J. C., Vissing, C. R., Madsen, K. L., Heinicke, K., Sharp, L., Phillips, L. T., Romain, N., Park, S. Y., Newby, M., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.08.007 · Cited by 25 · cited 2×
“Mutations in PGM1 cause GSD type XIV, which is also a congenital disorder of protein N-glycosylation [26].”
BackgroundSevere Axial Myopathy in McArdle Disease
Witting, N., Dunø, M., Piraud, M., & Vissing, J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3209 · Cited by 24 · cited 1×
“In a recent case report of a 61 year old male with exercise-induced pain since age three, weight loss and creatine-kinase (CK) values up to 4000 U/L and severe axial myopathy with predominant affection of the paraspinal muscles has been described [25].”
BackgroundLu, Y., Zhao, D., Yao, S., Wu, S., Hong, D., Wang, Q., Liu, J., Smeitink, J. A. M., Yuan, Y., & Wang, Z. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.05.056 · Cited by 24
Start codon mutation of GYG1 causing late-onset polyglucosan body myopathy with nemaline rods
Tasca, G. A., Fattori, F., Monforte, M., Hedberg‐Oldfors, C., Sabatelli, M., Udd, B., Boldrini, R., Bertini, E., Ricci, E., & Oldfors, A. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8268-z · Cited by 23 · cited 1×
“The complete absence of GYG1 may only cause a very late-onset asymptomatic myopathy [30].”
BackgroundObaid, A., Nashabat, M., Alfadhel, M., AlAsmari, A. M., Mutairi, F. A., Alswaid, A. F., Faqeih, E., Mushiba, A. M., Albanyan, M., Alalwan, M., et al. (2017) · JIMD Reports · doi:10.1007/8904_2017_58 · Cited by 23 · cited 1×
“ACADVL VLCADD Beta-oxidation No Yes (cardiomyopathy, retardation, hepatopathy) [43]”
MethodMitochondrial dysfunction in human skeletal muscle biopsies of lipid storage disorder
Bandopadhyay, D., Kumar, M., Prasad, T. S. K., Natarajan, A., Christopher, R., Nalini, A., Bindu, P. S., Gayathri, N., & Bharath, M. M. S. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14318 · Cited by 22 · cited 6×
“Carnitine is effective in treating PCD and MADD.”
BackgroundInfluentialMultiorgan disorder syndrome (MODS) in an octagenarian suggests mitochondrial disorder
Finsterer, J., & Bastovansky, A. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000900016 · Cited by 21 · cited 1×
“Clinical manifestations of MIDs are manifold and in the majority of cases, MIDs manifest as MIMODS frequently involving the muscle [51].”
BackgroundSelf-citationTonin, P., Bruno, C., Cassandrini, D., Savio, C., Tavazzi, E., Tomelleri, G., & Piccolo, G. (2009) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.08.007 · Cited by 21
Polyglucosan myopathy and functional characterization of a novel GYG1 mutation
Hedberg‐Oldfors, C., Mensch, A., Visuttijai, K., Stoltenburg, G., Stoevesandt, D., Kraya, T., Oldfors, A., & Zierz, S. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12865 · Cited by 18 · cited 3×
“However, phenotypes with distal muscle weakness have also been reported, even in the same family [6].”
BackgroundCohen, I., Staretz‐Chacham, O., Wormser, O., Perez, Y., Saada, A., Kadir, R., & Birk, O. S. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38574 · Cited by 18 · cited 1×
“SLC25A1 nDNA complex-V ↓ No Yes (cognitive impairment) [58]”
Li, S., Hwu, W., Lin, J.-L., Bali, D. S., Yang, C., Chu, S., Chien, Y., Chou, H., Chen, C., Hsieh, W., et al. (2011) · Journal of Child Neurology · doi:10.1177/0883073811415107 · Cited by 17 · cited 1×
“GBE1 GSD IV No Yes (cardiomyopathy, hepatopathy) [12]”
BackgroundMitochondrial myopathy with autophagic vacuoles in patients with the m.8344A>G mutation
Yuan, J., Sakiyama, Y., Higuchi, I., Inamori, Y., Higuchi, Y., Hashiguchi, A., Higashi, K., Yoshimura, A., & Takashima, H. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201431 · Cited by 17
Patients with neutral lipid storage disease with myopathy (NLSDM) in Southwestern China
Tan, J.-Z., Yang, H., Fan, J., Fan, Y., & Xiao, F. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.03.001 · Cited by 17 · cited 1×
“PNPLA2 NLSD-M ATGL ↓ No Yes (cardiomyopathy) [35,40]”
Gourzi, P., Pantou, M. P., Gkouziouta, A., Kaklamanis, L., Tsiapras, D. P., Zygouri, C., Constantoulakis, P., Adamopoulos, S. N., & Degiannis, D. (2018) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2018.05.015 · Cited by 17 · cited 1×
“Due to the rarity of the disease, there is little understanding of the genotype–phenotype correlation and the broad phenotypic heterogeneity of the disease [83].”
BackgroundGültekin, G. İ., Hekimoglu, B. T., Görmez, Z., Gelişin, Ö., Durmuş, H., Ergüner, B., Demirci, H., Sağıroğlu, M. Ş., Parman, Y., Deymeer, F., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.06.004 · Cited by 15
Asymptomatic Young Man with Danon Disease
Kim, J. J., Parikh, P. J., Mahboob, M. R. D., Arrighi, J. A., Atalay, M. K., Rowin, E. J., & Maron, M. S. (2014) · Texas Heart Institute Journal · doi:10.14503/thij-13-3279 · Cited by 14 · cited 1×
“Rarely, Danon disease manifests without myopathy or mental impairment but exclusively with cardiomyopathy [85,86].”
BackgroundMotzek, A., Knežević, J., Switzeny, O. J., Cooper, A., Barić, I., Belužić, R., Strauss, K. A., Puffenberger, E. G., Mudd, S. H., Vugrek, O., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151261 · Cited by 14 · cited 1×
“AHCY Purine No Yes (encephalopathy, hypotonia) [69]”
Ischemic stroke due to hypoperfusion in a patient with a previously unrecognized Danon disease
Marino, M., Musumeci, O., Paleologo, G., Cucinotta, M. D., Migliorato, A., Rodolico, C., & Toscano, A. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.09.025 · Cited by 14 · cited 1×
“Cardiomyopathy in LAMP2 carriers may be associated with conduction defects, such as Wolf–Parkinson–White syndrome, which may be complicated by cardiac arrest secondarily leading to ischemic stroke [82].”
BackgroundMyoadenylate deaminase deficiency in children
Ashwal, S., & Peckham, N. H. (1985) · Pediatric Neurology · doi:10.1016/0887-8994(85)90062-1 · Cited by 13 · cited 1×
“MADA Purine Yes Yes (cardiomyopathy) [70]”
Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease
Chien, Y., Hwu, W., Lee, N., Tsai, F., Koeberl, D. D., Tsai, W., Chiu, P.-C., & Chang, C. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.04.004 · Cited by 13 · cited 1×
“Recently, it has been shown that albuterol could be an adjunctive therapy for patients with EOPD, although the overall benefit seems to be limited [91].”
Backgroundvan Vliet, P., Berden, A., van Schie, M. V., Bakker, J., Heringhaus, C., de Coo, I. D., Langeveld, M., Schroijen, M., & Arbous, M. (2017) · JIMD Reports · doi:10.1007/8904_2017_37 · Cited by 13 · cited 1×
“HADHB MTPD Beta-oxidation No Yes (cardiomyopathy, neuropathy) [42]”
BackgroundLuo, S.-S., Xi, J., Cai, S., Zhao, C., Lu, J., Zhu, W., Lin, J., Qiao, K., Wang, Y., & Ye, Z. (2014) · Clinical Neuropathology · doi:10.5414/np300668 · Cited by 12 · cited 1×
“Myopathy in Danon disease may show a fluctuating course and may be easily misdiagnosed until a muscle biopsy shows typical vacuolar myopathy [79].”
BackgroundFinsterer, J., Wanschitz, J., Quasthoff, S., Iglseder, S., Löscher, W. N., & Grisold, W. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12758 · Cited by 12 · cited 13×
“Nomenclature List of Abbreviations AD Autosomal dominant AR Autosomal recessive CPT-II Carnitine-palmitoyl-transferase deficiency DBS Dried blood spot test EALS Endosomal autophagic lysosomal system EOPD Early onset Pompe disease ERT Enzyme replacement therapy FAOD Fatty acid oxidation disorder FAUD Fatty acid uptake…”
BackgroundSelf-citationDesikan, M., Scalco, R., Manole, A., Gardiner, A., Schapira, A. H. V., Lachmann, R., Houlden, H., Holton, J. L., Phadke, R., & Quinlivan, R. C. M. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.01.002 · Cited by 12 · cited 8×
“Extensive deposition of polyglucosan was found in myocytes and cardiomyocytes, hence the term PGBM-1 was adopted [34].”
BackgroundInfluentialBalasubramanian, M., Jenkins, T. M., Kirk, R., Nesbitt, I. M., Olpin, S. E., Hill, M., & Gillett, G. T. (2018) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2018.02.008 · Cited by 12 · cited 6×
“Ser113Leu mutation accounts for about 60% of cases [41].”
BackgroundInfluentialMetabolic Myopathies and the Respiratory System
Koo, P., & Sethi, J. M. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.02.001 · Cited by 12 · cited 3×
“Metabolic myopathies (MMs) are a heterogeneous group of metabolic disorders characterized by defects of enzymatic pathways involved in myocyte metabolism (inborn errors of metabolism) [1].”
BackgroundInfluentialDing, Y., Li, N., Chang, G., Li, J., Yao, R., Shen, Y., Wang, J., Huang, X., & Wang, X. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0551 · Cited by 12
Differential diagnosis of vacuolar muscle biopsies: use of p62, LC3 and LAMP2 immunohistochemistry.
Vittonatto, E., Boschi, S., Chiado'-Piat, L., Ponzalino, V., Bortolani, S., Brusa, C., Rainero, I., Ricci, F., Vercelli, L., & Mongini, T. (2017) · Europe PMC (PubMed Central) · Cited by 11
Enzymatic replacement therapy in patients with late-onset Pompe disease – 6-Year follow up
Witkowski, G., Konopko, M., Rola, R., Ługowska, A., Ryglewicz, D., & Sienkiewicz‐Jarosz, H. (2018) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2018.05.002 · Cited by 11
Screening for late-onset Pompe disease in western Denmark
Hansen, J. S., Pedersen, E. G., Gaist, D., Bach, F. W., Vilholm, O. J., Sandal, B. F., Weitemeyer, L., Nielsen, K., Schlesinger, F. E., Preisler, N. R., et al. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12811 · Cited by 10 · cited 1×
“Only few patients with LOPD may have normal GAA activity [72].”
BackgroundMPV17-Related Mitochondrial DNA Maintenance Defect
El‐Hattab, A. W., Wang, J., Dai, H., Almannai, M., Scaglia, F., Craigen, W. J., & Wong, L. C. (2018) · Europe PMC (PubMed Central) · Cited by 10
Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa
Horvath, J. J., Austin, S. L., Jones, H. N., Drake, E. J., Case, L. E., Soher, B. J., Bashir, M. R., & Kishnani, P. S. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.09.025 · Cited by 9 · cited 1×
“In a study of three patients with GSD IIIa, bulbar muscle involvement with fatty infiltration at the base of the intrinsic tongue musculature has been reported [24].”
BackgroundMitochondrial DNA Deletions With Low-Level Heteroplasmy in Adult-Onset Myopathy
Leung, D. G., Cohen, J. S., Michelle, E. H., Bai, R., Mammen, A. L., & Christopher‐Stine, L. (2018) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000200 · Cited by 9
Cucchiari, D., Colombo, I., Amato, O., Podestà, M. A., Reggiani, F., Valentino, R., Faravelli, I., Testolin, S., Moggio, M. G., & Badalamenti, S. (2017) · CEN Case Reports · doi:10.1007/s13730-017-0292-z · Cited by 7 · cited 1×
“Strenuous exercise may induce severe rhabdomyolysis in children and adults with consecutive renal failure in these patients [49].”
BackgroundZhang, Y., Xu, M., Chen, X., Yan, A., Zhang, G., Liu, Z., & Qiu, W. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0560-6 · Cited by 7 · cited 5×
“2590 C > T were identified as causative [11].”
BackgroundInfluentialDistinct Clinical and Genetic Findings in Iranian Patients With Glycogen Storage Disease Type 3
Nazari, F., Sinaei, F., Nilipour, Y., Petit, F. M., Oveisgharan, S., Toosi, M. N., Razzaghy‐Azar, M., Mahmoudi, M., & Nafissi, S. (2018) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000212 · Cited by 7 · cited 1×
“In a study of five Iranian patients with GSD IIIa, three patients had typical liver involvement in childhood, and four developed vacuolar myopathy [22].”
BackgroundPhowthongkum, P., Ittiwut, C., & Shotelersuk, V. (2017) · JIMD Reports · doi:10.1007/8904_2017_74 · Cited by 6 · cited 1×
“CPT-II deficiency can present antenatally as congenital brain malformations [48].”
BackgroundKyaw, H., Shaik, F., Lin, A., & Shinnar, M. (2018) · Cureus · doi:10.7759/cureus.2155 · Cited by 6
McIntosh, P. T., Austin, S. L., Sullivan, J. A., Bailey, L. A., Bailey, C., Viskochil, D. H., & Kishnani, P. S. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38369 · Cited by 5 · cited 1×
“To assess the risk of relatives of an index patient, enzymology (GAA activity assay) is recommended as the initial screening test before targeted mutation analysis is carried out [73,74].”
BackgroundRojas, C. M., Toro, M., Hincapié, M. E. S., Enríquez, M. R. I., di Filippo, D., López, J. Á., Baquero, C., Navas, M. C., & Arias, A. A. (2017) · Biomédica · doi:10.7705/biomedica.v38i0.3454 · Cited by 4 · cited 2×
“AGL GSD III No Yes (hepatopathy, cardiomyopathy, seizures, retardation) [10,11]”
Background2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease
Plöckinger, U., Prasad, V., Ziagaki, A., Tiling, N., & Poellinger, A. (2018) · Human Genomics · doi:10.1186/s40246-018-0145-7 · Cited by 3
Pompe disease: An Indian series diagnosed on muscle biopsy by ultrastructural characterization
Kakkar, A., Sharma, M. C., Nambirajan, A., Gulati, S., Bhatia, R., Suri, V. S., & Sarkar, C. (2018) · Ultrastructural Pathology · doi:10.1080/01913123.2018.1447624 · Cited by 3 · cited 5×
“PD is characterized by glycogen storage in lysosomes and the cytoplasm of myocytes, cardiomyocytes, and other cell types [9].”
BackgroundInfluentialMatsuishi, T., Yuge, K., Aramaki, S., Yoshino, M., Yoshida, I., & Yamashita, F. (1988) · Brain and Development · doi:10.1016/s0387-7604(88)80083-4 · Cited by 2 · cited 5×
“Disorders of lipid metabolism may go along with lipid storage in muscle cells (lipid storage diseases/myopathies (LSMs)) or without intracellular lipid storage [35].”
BackgroundInfluential(2011) · Thieme eBooks · doi:10.1055/b-0034-29598 · Cited by 1
Research works printed but not linked: 1
- Finsterer J. Metabolische Myopathien Jatr. Neurol. Psychiatr. 2011 4 26 27
Cited by
van den Bersselaar, L. R., Heytens, L., da Silva, H. C. A., Reimann, J., Tasca, G. A., Díaz‐Cambronero, Ó., Løkken, N., Hellblom, A., Hopkins, P. M., Rueffert, H., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15526 · Cited by 73
“• Infants with hypotonia due to a metabolic disease, the group at risk for propofol infusion syndrome [54– 56], usually present with global developmental delay or other neurological signs, for example, epilepsy and spasticity [22, 91, 92].”
BackgroundRybalka, E., Park, H. J., Nalini, A., Baskar, D., Polavarapu, K., Durmuş, H., Xia, Y., Wan, L., Shieh, P. B., Moghadaszadeh, B., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03429-x · Cited by 14
Filamented Light (FLight) Bioprinting of Mini‐Muscles with Self‐Renewal Potential
Liu, H., Winkelbauer, M., Janiak, J., Weber, P., Kalkan, A. K., Kim, I., Chansoria, P., Bar‐Nur, O., & Zenobi‐Wong, M. (2025) · Advanced Materials · doi:10.1002/adma.202501147 · Cited by 22
Update on Exercise in Persons With Muscle Disease
Mamarabadi, M., Kudritzki, V., Li, Y., & Howard, I. M. (2025) · Muscle & Nerve · doi:10.1002/mus.28356 · Cited by 12
Ijaz, A., Abbas, S., Shabbir, M., Badshah, Y., Abid, F., Afsar, T., & Razak, S. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03979-8 · Cited by 15
Metadata
- Authors
- Finsterer, J.
- Affiliations
- Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
- Corresponding author
- Finsterer, Josef
- ORCID
- Finsterer, Josef
- Venue
- Life
- Publisher
- MDPI AG
- Published
- 2020-04-17
- Volume
- 10
- Issue
- 4
- Pages
- 43
- ISSN
- 2075-1729 (ISSN-L)
- PMC
- PMC7235760
- OpenAlex
- W3017154056
- Cited by
- 31
- References
- 98
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 3
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Life (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- metabolic myopathies, hereditary muscle disease, muscle metabolism, exercise intolerance, creatine kinase, myoglobinuria, PGM1, RBCK1, MTO1, Kars, genetic diagnosis, next-generation sequencing, neuromuscular disorders, pathophysiology, treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.